All Drug Discovery articles
-
NewsVitronectin protein identified as key driver of lung scarring
Researchers from UTS and Monash University have identified vitronectin as a key protein driving abnormal lung scarring in idiopathic pulmonary fibrosis, opening a potential new avenue for therapeutic intervention in a disease with very few treatment options.
-
NewsPancreas organoids reveal CFTR dysfunction as chronic pancreatitis drug target
Researchers at the Salk Institute have developed a patient-derived organoid platform that identifies distinct biological subtypes of chronic pancreatitis and highlights CFTR as a potential therapeutic target, raising prospects for more personalised treatments.
-
NewsNTX-301 targets treatment-resistant AML via Hippo pathway in preclinical study
A novel epigenetic therapy has demonstrated activity against treatment-resistant acute myeloid leukaemia in preclinical models, including high-risk TP53-mutant disease, by selectively reactivating the Hippo tumour-suppressor pathway.
-
NewsNew BET therapies could help beat resistance in solid cancers
A new review finds that next-generation BET-targeted therapies, including selective inhibitors and PROTACs, are addressing the clinical shortcomings of earlier compounds and reviving interest in this approach for solid tumour treatment.
-
NewsAUTAC strategy targets MCL1 to overcome myeloma treatment resistance
Scientists at VCU Massey Comprehensive Cancer Center have developed an autophagy-targeting chimera that redirects cancer cells’ own recycling machinery to degrade the survival protein MCL1, offering a potential new strategy to overcome treatment resistance in multiple myeloma.
-
WebinarBuilding better therapeutic antibodies: the science, progress and problems to solve
As therapeutic antibodies become more complex, where is the field making real progress and which problems are proving hardest to solve? Hear leading experts share their perspectives.
-
NewsNew BET inhibitors could overcome barriers in solid tumour treatment
A new review examines how advances in drug design, PROTAC degraders and combination therapies are reviving the clinical prospects of BET inhibition in solid tumours, after early-generation compounds were hampered by toxicity, resistance and modest efficacy.
-
ArticleOrgan chips move closer to drug discovery pipelines
From uncovering new drug targets to predicting human toxicity, organ chips are showing what they could bring to drug discovery. Professor Donald Ingber of Harvard University discusses where the technology is heading next.
-
NewsKCL-286 targets multiple Alzheimer’s pathways in preclinical study
A repurposed small molecule originally developed for spinal cord injury has demonstrated the ability to address multiple disease-relevant pathways in Alzheimer’s disease, including DNA damage and neuroinflammation, offering a potential route to disease-modifying therapy.
-
NewsInsilico Medicine launches Phase III trial of AI-designed Rentosertib drug
Insilico Medicine has advanced its AI-discovered TNIK inhibitor Rentosertib into a 320-patient Phase III trial for idiopathic pulmonary fibrosis, marking a landmark moment for generative AI drug discovery.
-
ArticleAI’s real value in drug discovery may be choosing the right experiment
AI is becoming more capable, but its value still depends on the data, questions and decisions behind it. Where is it genuinely improving drug discovery and where do the limitations remain?
-
NewsAI and lab techniques accelerate tuberculosis drug discovery
Researchers at UMass Amherst have combined high-throughput laboratory screening with an AI neural network to identify compounds capable of breaching the protective outer membrane of Mycobacterium tuberculosis, potentially accelerating the search for new TB therapeutics.
-
Newsbit.bio launches iPSC-derived cell culture media kits to democratise human cell research
Cambridge-based cell programming company bit.bio has introduced two new media kits for its iPSC-derived ioGlutamatergic Neurons and ioMicroglia, reducing media preparation costs by around 18-fold and simplifying workflows to widen access to human-relevant research models.
-
NewsXL20 drug candidate shields motor neurons from ALS-linked TDP-43 damage
A newly identified experimental compound, XL20, has demonstrated neuroprotective effects in mouse models and human motor neurons by targeting a conserved disease-linked region of TDP-43, a protein central to ALS pathology.
-
NewsATRX mutations reprogram chromatin to drive glioma progression
Scientists at MD Anderson Cancer Center have revealed how ATRX mutations restructure chromatin and activate oncogenic developmental pathways in glioma, pointing towards novel therapeutic targets including the HOXA signalling axis.
-
NewsFish-inspired sensor detects heartbeat of lab-grown cardiac organoids
A biomechanical well plate inspired by the pressure-sensing lateral line of fish can wirelessly monitor the pulse of multiple lab-grown cardiac organoids simultaneously, offering a scalable new platform for cardiovascular drug testing.
-
NewsMETTL3 protein finds new mechanism driving breast cancer metastasis
Scientists at Umeå University have uncovered a previously unknown function for the RNA-modifying protein METTL3, revealing it plays a distinct role in enabling breast cancer cells to invade surrounding tissue and form metastases – findings that could open new avenues for therapeutic targeting.
-
NewsTranexamic acid cuts post-hepatectomy liver failure risk threefold
An international multi-centre study has found that tranexamic acid, a widely available and inexpensive haemostatic agent, could reduce the risk of post-hepatectomy liver failure threefold, offering a potential new preventive strategy for one of liver surgery’s most feared complications.
-
NewsHidden vulnerability in persister cells could prevent KRAS cancer relapse
Scientists at Chiba University have identified a metabolic vulnerability in drug-tolerant cancer cells that survive KRAS-targeted therapy, opening a potential route to combination treatments designed to prevent disease recurrence in lung, pancreatic and colorectal cancers.
-
InterviewThe global push to reduce animal testing in drug development
Non-animal methods are already used throughout early drug discovery, yet animal testing continues to dominate regulatory safety assessment. Recent initiatives suggest change is coming, but significant scientific and practical challenges remain.